Time-course of neopterin levels in patients suffering from severe sepsis treated with and without Drotrecogin-alpha (activated)

Scandinavian Journal of Infectious Diseases

Volumn 40, Issue 6-7, 2008, Pages 503-508

  Behnes, Michael ^a   Brueckmann, Martina ^a   Wiessner, Mike ^a   Kettenmann, Eva ^a   Liebetrau, Claudia ^a   Lang, Siegfried ^a   Putensen, Christian ^b   Borggrefe, Martin ^a   Hoffmann, Ursula ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BILIRUBIN; C REACTIVE PROTEIN; CREATININE; D DIMER; DROTRECOGIN; NEOPTERIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENTEROHEPATIC CIRCULATION; FEMALE; HUMAN; KIDNEY FUNCTION; LEUKOCYTE COUNT; MALE; PROTEIN BLOOD LEVEL; SEPSIS; THROMBOCYTE COUNT; TIME SERIES ANALYSIS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BILIRUBIN; CREATININE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPTERIN; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; STATISTICS AS TOPIC; TIME FACTORS;

EID: 47349131517     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540701808978     Document Type: Article

References (24)

1. Fuchs, D., Weiss, G., Reibnegger, G. and Wachter, H. (1992) The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci, 29, pp. 307-341.
2. Huber, C., Batchelor, JR, Fuchs, D., Hausen, A., Lang, A. Niederwieser, D. et al. (1984) Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med, 160, pp. 310-316.
3. Werner, ER, Werner-Felmayer, G., Fuchs, D., Hausen, A., Reibnegger, G. Yim, JJ et al. (1990) Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1, and T-24 cells. GTP-cyclohydrolase I is stimulated by interferon-gamma, and 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase are constitutively present. J Biol Chem, 265, pp. 3189-3192.
4. Nathan, CF. (1986) Peroxide and pteridine: A hypothesis on the regulation of macrophage antimicrobial activity by interferon-gamma. Interferon, 7, pp. 125-143.
5. Reibnegger, G., Aichberger, C., Fuchs, D., Hausen, A., Spielberger, M. Werner, ER et al. (1991) Post-transplant neopterin excretion in renal allograft recipients: A reliable diagnostic aid for acute rejection and a predictive marker of long-term graft survival. Transplantation, 52, pp. 58-63.
6. Horneff, G., Sack, U., Kalden, JR, Emmrich, F. and Burmester, GR. (1993) Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis. Clin Exp Immunol, 91, pp. 207-213.
7. Reibnegger, G., Fuchs, D., Fuith, LC, Hausen, A., Werner, ER Werner-Felmayer, G. et al. (1991) Neopterin as a marker for activated cell-mediated immunity: Application in malignant disease. Cancer Detect Prev, 15, pp. 483-490.
8. Brown, AE, Herrington, DA, Webster, HK, Clyde, DF, Sztein, MB Davis, JR et al. (1992) Urinary neopterin in volunteers experimentally infected with Plasmodium falciparum. Trans R Soc Trop Med Hyg, 86, pp. 134-136.
9. Fuchs, D., Jager, H., Popescu, M., Reibnegger, G., Werner, ER Dierich, MP et al. (1990) Immune activation markers to predict AIDS and survival in HIV-1 seropositives. Immunol Lett, 26, pp. 75-79.
10. Strohmaier, W., Redl, H., Schlag, G. and Inthorn, D. (1987) D-erythro-neopterin plasma levels in intensive care patients with and without septic complications. Crit Care Med., 15, pp. 757-760.
11. Hensler, T., Sauerland, S., Lefering, R., Nagelschmidt, M., Bouillon, B. Andermahr, J. et al. (2003) The clinical value of procalcitonin and neopterin in predicting sepsis and organ failure after major trauma. Shock, 20, pp. 420-426.
12. Bone, RC, Grodzin, CJ and Balk, RA. (1997) Sepsis: A new hypothesis for pathogenesis of the disease process. Chest, 112, pp. 235-243.
13. Dhainaut, JF, Shorr, AF, Macias, WL, Kollef, MJ, Levi, M. Reinhart, K. et al. (2005) Dynamic evolution of coagulopathy in the first day of severe sepsis: Relationship with mortality and organ failure. Crit Care Med, 33, pp. 341-348.
14. Hughes, M. (2006) Recombinant human activated protein C. Int J Antimicrob Agents, 28, pp. 90-94.
15. Bernard, GR, Vincent, JL, Laterre, PF, LaRosa, SP, Dhainaut, JF Lopez-Rodriguez, A. et al. (2001) Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med, 344, pp. 699-709.
16. Dhainaut, JF, Yan, SB, Joyce, DE, Pettila, V., Basson, B. Brandt, JT et al. (2004) Treatment effects of Drotrecogin-alpha (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost, 2, pp. 1924-1933.
17. Dhainaut, JF, Yan, SB, Margolis, BD, Lorente, JA, Russell, JA Freebairn, RC et al. (2003) PROWESS Sepsis Study Group. Drotrecogin-alpha (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost, 90, pp. 642-653.
18. Bone, RC, Balk, RA, Cerra, FB, Dellinger, RP, Fein, AM Knaus, WA et al. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest, 101, pp. 1644-1655.
19. Knaus, WA, Draper, EA, Wagner, DP and Zimmerman, JE. (1985) APACHE II: A severity of disease classification system. Crit Care Med, 13, pp. 818-829.
20. Yan, SC, Razzano, P., Chao, YB, Walls, JD, Berg, DT McClure, DB et al. (1990) Characterization and novel purification of recombinant human protein C from 3 mammalian cell lines. Biotechnology (N Y), 8, pp. 655-661.
21. Czeslick, EG, Nestler, F., Simm, A., Struppert, A. and Sablotzki, A. (2005) Drotrecogin-alpha (activated) does not affect intracellular production of interleukin-6 and tumour necrosis factor-alpha in endotoxin-stimulated human monocytes. Anesth Analg, 101, pp. 1805-1808.
22. Brueckmann, M., Hoffmann, U., De Rossi, L., Weiler, HM, Liebe, V. Lang, S. et al. (2004) Activated protein C inhibits the release of macrophage inflammatory protein-1 from THP-1 cells and from human monocytes. Cytokine, 26, pp. 106-113.
23. Brueckmann, M., Hoffmann, U., Dvortsak, E., Lang, S., Kaden, JJ Borggrefe, M. et al. (2004) Drotrecogin-alpha (activated) inhibits NF-kappa B activation and MIP-1 release from isolated mononuclear cells of patients with severe sepsis. Inflamm Res, 53, pp. 528-533.
24. Weiss, G., Glaser, K., Kronberger, P., Ambach, E., Fuchs, D. Bodner, E. et al. (1992) Distinct distributions of D-erythro-neopterin in arteries and veins and its recovery by an enterohepatic circulation. Biol Chem Hoppe Seyler, 373, pp. 289-294.